tiprankstipranks
Trending News
More News >
Jaguar Animal Health (JAGX)
NASDAQ:JAGX
Advertisement

Jaguar Animal Health (JAGX) AI Stock Analysis

Compare
2,343 Followers

Top Page

JAGX

Jaguar Animal Health

(NASDAQ:JAGX)

Rating:42Neutral
Price Target:
$2.50
▲(37.36% Upside)
Jaguar Animal Health's overall stock score is primarily impacted by its weak financial performance, characterized by high leverage and negative cash flows. Technical indicators and valuation metrics further contribute to a cautious outlook. While recent earnings call and corporate events show some positive developments, they are overshadowed by the company's financial struggles.

Jaguar Animal Health (JAGX) vs. SPDR S&P 500 ETF (SPY)

Jaguar Animal Health Business Overview & Revenue Model

Company DescriptionJaguar Animal Health, Inc. (JAGX) is a biotechnology company focused on developing and commercializing innovative animal health products for the veterinary market. The company specializes in the development of therapeutics for companion animals and livestock, particularly targeting gastrointestinal health and other unmet medical needs. Jaguar's core products include a range of prescription medications and nutraceuticals aimed at enhancing the health and well-being of animals, leveraging its proprietary technology platforms to create effective solutions.
How the Company Makes MoneyJaguar Animal Health generates revenue primarily through the sale of its pharmaceutical products and veterinary therapeutics. The company has established a revenue model that includes direct sales to veterinarians and animal health distributors, as well as partnerships with larger pharmaceutical companies for product development and distribution. Key revenue streams include prescription medications and potential royalties from collaborations. Additionally, Jaguar may engage in licensing agreements for its proprietary technologies, further enhancing its financial performance. Significant partnerships with veterinary practices and discussions with animal food companies also contribute to its earnings, as they help broaden the reach and application of its products in the market.

Jaguar Animal Health Earnings Call Summary

Earnings Call Date:Aug 14, 2025
(Q2-2025)
|
% Change Since: -29.73%|
Next Earnings Date:Nov 12, 2025
Earnings Call Sentiment Neutral
The earnings call presented a positive outlook with significant revenue growth and successful clinical trial results for crofelemer, along with strategic regulatory advancements and expansion plans in the animal health market. However, these positive developments were offset by increased operational losses and net loss attributable to shareholders.
Q2-2025 Updates
Positive Updates
Significant Revenue Growth
The second quarter of 2025 saw a combined net revenue of approximately $3 million, representing a 35% increase compared to Q1 2025 and a 10% increase compared to Q2 2024.
Positive Clinical Trial Results for Crofelemer
Initial proof-of-concept results from a study in Abu Dhabi demonstrated that crofelemer reduced the required TPN and supplementary intravenous fluids in MVID and SBS patients by up to 27% and 12.5% respectively.
Regulatory Advancements for Crofelemer
Jaguar participated in an FDA Type C meeting, discussing two pathways for crofelemer's availability for metastatic breast cancer patients, highlighting an expanded access program and a pivotal treatment trial.
Expansion into Animal Health Market
Ongoing discussions with potential partners to expand Canalevia's approval from chemotherapy-induced diarrhea in dogs to general diarrhea in dogs globally.
Negative Updates
Increased Net Loss
Net loss attributable to common shareholders increased by approximately $900,000 from $9.5 million in Q2 2024 to $10.4 million in Q2 2025.
Loss from Operations
Loss from operations increased by $800,000 from $7.2 million in Q2 2024 to $8 million in Q2 2025.
Company Guidance
During the earnings call for the second quarter of 2025, Jaguar Health reported a combined net revenue of approximately $3 million, marking a 35% increase compared to the first quarter of 2025 and a 10% increase compared to the second quarter of 2024. Mytesi prescription volume rose by 6.5% over the previous quarter. However, the company experienced a loss from operations of $8 million, an increase of $800,000 from the same period in 2024, and a net loss attributable to common shareholders of $10.4 million, up by $900,000. The non-GAAP recurring EBITDA showed a net loss reduction from $8.8 million in 2024 to $7.9 million in 2025. The financial guidance emphasized the importance of recent clinical and regulatory catalysts aiming to secure nondilutive funding and forge business development partnerships.

Jaguar Animal Health Financial Statement Overview

Summary
Jaguar Animal Health faces substantial financial challenges characterized by high leverage, consistent net losses, and negative cash flows. Despite some revenue growth and strong gross margins, the company struggles with operational inefficiencies and high debt levels.
Income Statement
35
Negative
Jaguar Animal Health has shown a mixed performance with inconsistent revenue growth. The revenue grew by approximately 18.38% from 2023 to 2024 but showed a decline previously. Gross profit margins are reasonably high, but the company struggles with negative EBIT and net income margins, indicating ongoing operational and profitability challenges.
Balance Sheet
30
Negative
The company's balance sheet indicates high leverage with a Debt-to-Equity ratio of approximately 5.63 in 2024, reflecting significant reliance on debt financing. The return on equity is negative due to consistent net losses, and the equity ratio is low, suggesting financial instability and potential risks related to excessive debt.
Cash Flow
40
Negative
Cash flow analysis reveals a negative trend in free and operating cash flows, although there was a slight improvement from 2023 to 2024. The company managed to secure significant financing cash flows, which have been covering operational deficits. However, the negative free cash flow to net income ratio highlights ongoing cash management issues.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue11.51M11.69M9.76M11.96M4.33M9.38M
Gross Profit9.47M9.73M7.72M9.94M2.00M6.11M
EBITDA-38.48M-36.66M-33.13M-33.38M-42.35M-28.74M
Net Income-39.73M-38.49M-41.30M-47.45M-60.25M-36.79M
Balance Sheet
Total Assets51.46M53.42M50.76M47.45M53.27M42.84M
Cash, Cash Equivalents and Short-Term Investments5.69M8.00M6.47M5.47M17.05M8.09M
Total Debt38.34M36.53M37.09M34.84M29.36M16.21M
Total Liabilities50.63M46.93M45.87M48.81M41.41M25.64M
Stockholders Equity1.78M9.77M4.96M-657.00K11.61M17.20M
Cash Flow
Free Cash Flow-29.87M-29.61M-33.24M-34.78M-34.98M-15.29M
Operating Cash Flow-29.65M-29.38M-33.24M-33.10M-34.97M-15.28M
Investing Cash Flow-231.00K-231.00K1.23M-1.68M-6.00K-7.00K
Financing Cash Flow23.90M31.20M34.23M23.18M43.94M19.49M

Jaguar Animal Health Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.82
Price Trends
50DMA
2.45
Negative
100DMA
4.42
Negative
200DMA
12.53
Negative
Market Momentum
MACD
-0.20
Positive
RSI
33.68
Neutral
STOCH
3.94
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JAGX, the sentiment is Negative. The current price of 1.82 is below the 20-day moving average (MA) of 2.11, below the 50-day MA of 2.45, and below the 200-day MA of 12.53, indicating a bearish trend. The MACD of -0.20 indicates Positive momentum. The RSI at 33.68 is Neutral, neither overbought nor oversold. The STOCH value of 3.94 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JAGX.

Jaguar Animal Health Risk Analysis

Jaguar Animal Health disclosed 65 risk factors in its most recent earnings report. Jaguar Animal Health reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Jaguar Animal Health Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.82B-0.16-39.78%2.19%21.38%-1.56%
42
Neutral
$3.68M-296.91%15.95%92.33%
39
Underperform
$15.86M-402.19%59.81%
39
Underperform
$5.25M-285.78%120.67%-456.33%
28
Underperform
$3.32M-49.58%67.95%
28
Underperform
$4.30M-340.81%94.99%
15
Underperform
$3.63M-231.27%85.78%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JAGX
Jaguar Animal Health
1.80
-27.45
-93.85%
GLMD
Galmed Pharmaceuticals
1.49
-2.11
-58.61%
SNGX
Soligenix
3.38
-0.71
-17.36%
REVB
Revelation Biosciences
2.93
-55.15
-94.96%
DRMA
Dermata Therapeutics
5.48
-12.42
-69.39%
SXTP
60 Degrees Pharmaceuticals, Inc.
1.30
-7.75
-85.64%

Jaguar Animal Health Corporate Events

Product-Related AnnouncementsShareholder MeetingsBusiness Operations and Strategy
Jaguar Health Announces Promising Trial Results
Positive
Aug 19, 2025

On August 19, 2025, Jaguar Health held its Annual Meeting of Stockholders, where seven proposals were approved, including the election of directors and amendments to stock plans. The company also announced promising results from trials of crofelemer for gastrointestinal conditions and outlined plans for regulatory pathways and business development partnerships, potentially impacting its market strategy and stakeholder interests.

Business Operations and StrategyRegulatory Filings and Compliance
Jaguar Health Extends Market Offering Agreement
Neutral
Aug 14, 2025

On August 14, 2025, Jaguar Health, Inc. announced an amendment to its At the Market Offering Agreement, extending Lucid Capital Markets, LLC’s role as a Manager until December 31, 2025. This amendment, filed with the SEC, ensures that Lucid will continue its managerial role alongside Ladenburg Thalmann & Co. Inc. until the end of 2025, after which Ladenburg will become the sole Manager unless further extended.

Private Placements and FinancingBusiness Operations and Strategy
Jaguar Animal Health Issues Series M Preferred Stock
Neutral
Jun 30, 2025

On June 27, 2025, Jaguar Health, Inc. entered into exchange agreements with Iliad Research and Trading, L.P. and Streeterville Capital, LLC, issuing Series M Preferred Stock in exchange for reductions in outstanding royalty interests. This strategic move allows Jaguar Health to manage its financial obligations while offering stakeholders a structured investment opportunity through the Series M Preferred Stock, which includes specific rights and limitations, impacting the company’s capital structure and market positioning.

Private Placements and FinancingBusiness Operations and Strategy
Jaguar Animal Health Extends Maturity Date for Notes
Neutral
Jun 24, 2025

On June 24, 2025, Jaguar Health, Inc. announced an extension of the maturity date for $2.57 million of convertible promissory notes from its March 2025 bridge financing, now maturing on January 30, 2026. This extension, involving participation from the company’s CEO, board members, and other investors, aims to support Jaguar’s strategic goals, including partnerships for non-dilutive funding and advancing development programs for crofelemer in treating various conditions.

Private Placements and FinancingBusiness Operations and Strategy
Jaguar Health Announces $1.5M Direct Stock Offering
Positive
May 22, 2025

On May 20, 2025, Jaguar Health, Inc. entered into a securities purchase agreement for a registered direct offering of 246,306 shares of common stock at $6.09 per share, expected to raise approximately $1.5 million. The offering, set to close around May 22, 2025, includes a concurrent private placement of unregistered warrants to purchase up to 492,612 shares. The proceeds will be used for corporate purposes, including working capital and debt repayment. H.C. Wainwright & Co. acted as the placement agent, receiving a fee and warrants as compensation. This move is part of Jaguar’s strategy to strengthen its financial position and support its operational and development goals.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 19, 2025